Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
AustraliaIPO:
06 September 2005Website:
http://www.gtglabs.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 27 Jun 2024 23:47:44 GMTDividend
Analysts recommendations
Institutional Ownership
GENE Latest News
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m.
A joint investigation into a data breach at DNA testing company has been launched by UK and Canadian watchdogs.
Genetic Technologies Limited (NASDAQ:GENE ) Q4 2023 Earnings Conference Call August 8, 2023 7:15 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Tony Di Pietro - Chief Financial Officer Carl Stubbings - Chief Commercial Officer Conference Call Participants Adrian Mulcahy Thank you for joining us, and afternoon for those joining us from the U.S. I'm really pleased to have both Simon Morriss, the Chief Executive Officer of Genetic Technologies; and Tony Di Pietro, the CFO of Genetic as well. So this morning, we are going to go through an Investor Update.
Genetic Technologies Limited (NASDAQ:GENE ) Q3 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Tony Di Pietro - Chief Financial Officer Conference Call Participants Adrian Mulcahy [Abrupt Start] FY 2023. I'm really pleased to have both Simon Morriss, the CEO; and Tony Di Pietro.
What type of business is Genetic Technologies Limited?
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
What sector is Genetic Technologies Limited in?
Genetic Technologies Limited is in the Healthcare sector
What industry is Genetic Technologies Limited in?
Genetic Technologies Limited is in the Diagnostics & Research industry
What country is Genetic Technologies Limited from?
Genetic Technologies Limited is headquartered in Australia
When did Genetic Technologies Limited go public?
Genetic Technologies Limited initial public offering (IPO) was on 06 September 2005
What is Genetic Technologies Limited website?
https://www.gtglabs.com
Is Genetic Technologies Limited in the S&P 500?
No, Genetic Technologies Limited is not included in the S&P 500 index
Is Genetic Technologies Limited in the NASDAQ 100?
No, Genetic Technologies Limited is not included in the NASDAQ 100 index
Is Genetic Technologies Limited in the Dow Jones?
No, Genetic Technologies Limited is not included in the Dow Jones index
When does Genetic Technologies Limited report earnings?
Next earnings report date is not announced yet